Clinical Trial Update: Intravenous n-3 Fatty Acids and Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillator (ICD)-Pacemaker [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating intravenous omega-3 fatty acids in patients with an implantable cardioverter-defibrillator/pacemaker has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sudden Cardiac Death
• Ventricular Tachycardia

Drugs mentioned

• Intravenous n-3 Fatty Acids (n-3 fatty acids (intravenous))

Snippet

Sponsor: Aalborg University Hospital | Conditions: Ventricular Tachycardia, Sudden Cardiac Death | Phase 1, Phase 2 | Status: COMPLETED